Home > Legislation > 115th Congress > H.Res.787

H.Res.787 - Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.115th Congress (2017-2018) |

Resolution

Hide Overview
Sponsor: Rep. Burgess, Michael C. [R-TX-26] (Introduced 03/19/2018)
Committees: House - Rules
Committee Reports: H. Rept. 115-613
Latest Action: House - 03/20/2018 Motion to reconsider laid on the table Agreed to without objection.  (All Actions)
Roll Call Votes: There have been 2 roll call votes

Tracker:

This bill has the status Agreed to in House

Here are the steps for Status of Legislation:

  1. Introduced
  2. Agreed to in House

More on This Bill

  • CBO Cost Estimates [0]

Subject — Policy Area:

Summary: H.Res.787 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for H.Res.787. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (03/19/2018)

Sets forth the rule for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes.